Analyst Ratings

CRWD Stock Could Soar 16%, Says Wedbush's Dan Ives: 'Coming In Very Strong With Healthy Momentum'

Rivian Stock Above $15, But UBS Sees Fair Value At $13 Amid Affordability Concerns

Rivian Stock Above $15, But UBS Sees Fair Value At $13 Amid Affordability Concerns

Newmont Soars With A New $60 Price Target, Leads S&P 500 Higher

Rivian Stock Above $15, But UBS Sees Fair Value At $13 Amid Affordability Concerns

Rivian Stock Above $15, But UBS Sees Fair Value At $13 Amid Affordability Concerns

Newmont Soars With A New $60 Price Target, Leads S&P 500 Higher

Newmont Soars With A New $60 Price Target, Leads S&P 500 Higher

Bank of America Calls New Gold A Buy, Lifts Price Target By 50%

Bank of America Calls New Gold A Buy, Lifts Price Target By 50%

CyberArk Stock Poised To Surge Nearly 22%, Says BofA: 'Metrics Show Continued Execution On All Fronts'

CyberArk Stock Poised To Surge Nearly 22%, Says BofA: 'Metrics Show Continued Execution On All Fronts'

Bank of America Calls New Gold A Buy, Lifts Price Target By 50%

Bank of America Calls New Gold A Buy, Lifts Price Target By 50%

CyberArk Stock Poised To Surge Nearly 22%, Says BofA: 'Metrics Show Continued Execution On All Fronts'

CyberArk Stock Poised To Surge Nearly 22%, Says BofA: 'Metrics Show Continued Execution On All Fronts'

Freeport-McMoRan Scores A Solid Q3, Analysts Say: 'Benefit From High Copper And Gold Prices'

Freeport-McMoRan Scores A Solid Q3, Analysts Say: 'Benefit From High Copper And Gold Prices'

MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds

MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds

Analyst Ratings Recent News

Microsoft's 'iPhone Moment': Shares Dip But Analysts Remain Positive After Ignite Event

Microsoft's 'iPhone Moment': Shares Dip But Analysts Remain Positive After Ignite Event

Updates for MSFT's Copilot AI assistant makes waves at Ignite conference, with one analyst calling it "quite literally a killer-app."

How Analyst Ratings Can Help You Pick The Right Stocks

How Analyst Ratings Can Help You Pick The Right Stocks

Looking Ahead Of Wall Street: MEI Pharma, Sarepta, Novavax & More

Looking Ahead Of Wall Street: MEI Pharma, Sarepta, Novavax & More

3 JPMorgan Bull Calls Hitting The Market

3 JPMorgan Bull Calls Hitting The Market

Analysts See In-Line Q1 For Nike Inc; Currency Impact Questioned

Analysts See In-Line Q1 For Nike Inc; Currency Impact Questioned

Benzinga's Top Upgrades

Benzinga's Top Upgrades